Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 97
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 13
States / cities: Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Amprenavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Miami, Florida • Honolulu, Hawaii • New York, New York + 3 more

Conditions: HIV-1
Interventions: Etravirine (TMC125), Optimized background regimen (OBR); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: Ritonavir, Saquinavir, Methadone hydrochloride; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 1 more

Conditions: HIV Infections
Interventions: Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 29
States / cities: San Francisco, California • Torrance, California • Boulder, Colorado + 23 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Emtricitabine, Lamivudine, Lopinavir/ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York • Stony Brook, New York + 1 more

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 16
States / cities: Palo Alto, California • San Francisco, California • Torrance, California + 10 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 4
States / cities: San Francisco, California • Stanford, California • Baltimore, Maryland

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: HIV Infections
Interventions: Amprenavir/ritonavir, Saquinavir/ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 18 more

Conditions: HIV Infections
Interventions: Ritonavir, Efavirenz, Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 3
States / cities: Los Angeles, California • Palo Alto, California • New Brunswick, New Jersey

Conditions: HIV Infections
Interventions: saquinavir [Invirase], Lopinavir/ritonavir, Emtricitabine/tenofovir disoproxil fumarate, Ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 19
States / cities: Hobson City, Alabama • Tucson, Arizona • Berkeley, California + 16 more

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Menlo Park, California • Stanford, California • Denver, Colorado + 12 more

Conditions: HIV Infections
Interventions: Ritonavir, saquinavir [Invirase]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 5
States / cities: Chicago, Illinois • Somers Point, New Jersey • Voorhees Township, New Jersey + 2 more

Conditions: HIV Infections
Interventions: Amprenavir/ritonavir, Saquinavir/ritonavir, Efavirenz; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 20 more

Conditions: HIV Infections, AIDS-Associated Nephropathy
Interventions: Nelfinavir mesylate, Saquinavir, Lamivudine, Stavudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients

GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.

Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease